BeOne Medicines Ltd
688235
Company Profile
Business description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene’s revenue.
Contact
c/o BeOne Medicines I GmbH
Aeschengraben 27
21st Floor
Basel4051
CHET: +41 616851900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
11,000
Stocks News & Analysis
stocks
James Hardie transfers of share listing to New York Stock Exchange
The change is a result of the controversial Azek acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.20 | 80.60 | -0.89% |
| CAC 40 | 7,798.22 | 24.45 | -0.31% |
| DAX 40 | 24,307.80 | 18.29 | 0.08% |
| Dow JONES (US) | 44,556.48 | 214.29 | 0.48% |
| FTSE 100 | 9,012.99 | 20.87 | 0.23% |
| HKSE | 24,994.14 | 168.48 | 0.68% |
| NASDAQ | 21,053.64 | 157.98 | 0.76% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,961.51 | 81.11 | 0.63% |
| S&P 500 | 6,332.94 | 36.15 | 0.57% |
| S&P/ASX 200 | 8,668.20 | 89.00 | -1.02% |
| SSE Composite Index | 3,559.79 | 25.31 | 0.72% |